4D pharma plc announced the appointment of John Beck as Chief Financial Officer (CFO) and member of the Company's management team, bringing over 30 years of experience in finance, including three previous positions as Chief Financial Officer of publicly traded life sciences companies. Mr. Beck has extensive investor and public relations, corporate governance, regulatory, and fundraising expertise. Most recently he was the Senior Vice President, Finance and CFO of Ritter Pharmaceuticals from May 2018 to May 2020, where he oversaw its successful merger with Qualigen Therapeutics Inc. Prior to that, Mr. Beck served as Executive Manager and CEO at Wellspring Water Technologies, LLC and CEO of West Tech Medical, LLC from October 2015 to May 2018. Mr. Beck also was the CFO and Senior Vice President of Finance and Operations of Ardea Biosciences from February 2008 to June 2012, where he raised over $160 million in public financings, executed a $400 million out-licensing transaction with Bayer Pharmaceuticals and completed a $1.2 billion merger with AstraZeneca. Mr. Beck also held positions as Senior Vice President of Finance, Treasurer and CFO of Metabasis Therapeutics, and the Director of Finance at Neurocrine Biosciences, leading both through successful NASDAQ IPOs. In addition, Mr. Beck currently serves on the Board of Directors of San Diego-based Artelo Biosciences, as a scientific advisor and mentor to the University of San Diego's student-run TRITON fund. Mr. Beck holds a B.A. in Accounting from the University of Washington, Seattle, a degree in theology from a Seattle area seminary and is a licensed CPA (inactive status) in the state of California.